Next Article in Journal
Drug-Resistant Tuberculosis Treatment Recommendation, and Multi-Class Tuberculosis Detection and Classification Using Ensemble Deep Learning-Based System
Next Article in Special Issue
Design, Synthesis, Biological Evaluation, and Molecular Dynamics Studies of Novel Lapatinib Derivatives
Previous Article in Journal
Automatic Production of [18F]F-DOPA Using the Raytest SynChrom R&D Module
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 16
Issue 1
10.3390/ph16010011
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase

by
Bilal Ahmad Khan
1,*,
Syeda Shamila Hamdani
1,
Saquib Jalil
2,
Syeda Abida Ejaz
3,
Jamshed Iqbal
2,
Ahmed M. Shawky
4,
Alaa M. Alqahtani
5,
Gamal A. Gabr
6,7,
Mahmoud A. A. Ibrahim
8,9,* and
Peter A. Sidhom
10
1
Department of Chemistry, University of Azad Jammu and Kashmir, Muzaffarabad 13100, Pakistan
2
Center for Advanced Drug Research, COMSATS University Islamabad, Abbottabad Campus, Abbottabad 22060, Pakistan
3
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
4
Science and Technology Unit (STU), Umm Al-Qura University, Makkah 21955, Saudi Arabia
5
Pharmaceutical Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah 21955, Saudi Arabia
6
Department of Pharmacology and Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
7
Agricultural Genetic Engineering Research Institute (AGERI), Agricultural Research Center, Giza 12619, Egypt
8
Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt
9
School of Health Sciences, University of KwaZulu-Natal, Westville, Durban 4000, South Africa
10
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2023, 16(1), 11; https://doi.org/10.3390/ph16010011
Submission received: 16 November 2022 / Revised: 10 December 2022 / Accepted: 12 December 2022 / Published: 22 December 2022
(This article belongs to the Special Issue Enzyme Inhibitors: Potential Therapeutic Approaches)
Browse Figures
Versions Notes

Abstract

:
New S-alkyl phthalimide 5a–f and S-benzyl 6a–d analogs of 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) were prepared by reacting 4 with N-bromoalkylphthalimide and CF3-substituted benzyl bromides in excellent yields. Spectroscopic techniques were employed to elucidate the structures of the synthesized molecules. The inhibition activity of newly synthesized molecules toward MAO-A, MAO-B, and AChE enzymes, was also assessed. All these compounds showed activity in the submicromolar range against all enzymes. Compounds 5a and 5f were found to be the most potent compounds against MAO-A (IC50 = 0.91 ± 0.15 nM) and MAO-B (IC50 = 0.84 ± 0.06 nM), while compound 5c showed the most efficient acetylcholinesterase inhibition (IC50 = 1.02± 0.65 μM). Docking predictions disclosed the docking poses of the synthesized molecules with all enzymes and demonstrated the outstanding potency of compounds 5a, 5f, and 5c (docking scores = −11.6, −15.3, and −14.0 kcal/mol against MAO-A, MAO-B, and AChE, respectively). These newly synthesized analogs act as up-and-coming candidates for the creation of safer curative use against Alzheimer’s illness.

1. Introduction

Alzheimer’s disease (AD) is a complex neurological disturbance associated with memory loss and language skills, as well as behavioral and psychological changes [1]. According to the Alzheimer’s Association report, about 0.47 billion people globally suffer from AD, and the number of patients will exceed 1.50 billion in 2050 [2]. AD is a multi-factorial pathological condition with several causes. Among these, the deposition of beta-amyloid fibers, the death of neural cells, and high levels of monoamine oxidase (MAO) and acetylcholinesterase (AChE) enzymes occur [3,4].
The MAO enzyme presents in the exterior membrane of mitochondria [5] and metabolizes a variety of dietary amines besides neurotransmitters [6]. There are two known variants of the MAO enzyme, MAO-A and MAO-B, which have 70% similarity in protein structure and can be found in different parts of the body, liver, and brain [7]. MAO-B catalyzes beta-phenylethylamine and benzylamine, while MAO-A preferably catalyzes serotonin, noradrenaline, and adrenaline [5]. The inhibition of these enzymes plays a key role in AD [8,9]. In addition to MAOs, the AChE enzyme is a target for AD management [10,11]. The inhibition of these neural enzymes (AChE and MAOs) possess neuroprotective effects and decreases oxidative stress [12], leading to an increased level of neurotransmitters in the pre-synaptic cleft [13]. A diversity of dual-inhibiting molecules has developed by merging the moieties for MAOs and AChE in one compound [14]. Different research groups have identified various chemical classes bearing benzylamine [15,16], coumarin [17], oxazole, triazole [18], indole [19], quinolinone [20], isoindoline [21], and oxadiazole [22], as potent inhibitors of the targeted enzymes. Among those classes, quinoline has gained much attention as a privileged scaffold for multi-targeting enzymes (MAOs and AChE).
1,3,4-Oxadiazole moiety is a heterocyclic skeleton with single O, two N, and two C atoms with compromised aromaticity and enhanced diene character [23]. Compounds belonging to this class of heterocycles have expressed a tumultuous therapeutic potential as antimicrobial [24,25,26,27], antiepileptic [28,29,30,31,32], anticancer [33,34,35,36], hypoglycemic [37,38,39,40], antiviral [41,42,43,44,45,46], and anti-inflammatory [47,48,49,50,51] agents. Meanwhile, the chemistry and biological potential of 1,3,4-oxadiazoles have been thoroughly reviewed recently [52,53,54,55,56,57]. The 1,3,4-oxadiazole moiety has become an established pharmacophore with wide availability in commercial drugs [55], including raltegravir (anti-HIV) [58], furamizole (antimicrobial) [59], nesapidil (vasodilator) [60], and zibotentan (anticancer) [61]. Similarly, LC-150444 is a 1,3,4-oxadiazole-bearing potential drug in the preclinical testing stage for the inhibition of dipeptidyl peptidase IV (DPP IV) enzyme [39]. The chemical structures of these 1,3,4-oxadiazole-bearing chemical entities are depicted in Figure 1.
Quinoline, a fused structure of benzene and pyridine at two adjacent carbon atoms, is known to possess diverse biological and pharmaceutical potential. Naturally occurring quinoline-containing compounds and synthetic derivatives of quinoline have shown enormous potential to be used as medicine or lead compounds for drug development [62]. Naturally occurring quinine found in the bark of the cinchona plant and synthetic derivatives possessing a quinoline skeleton have been fruitfully employed for the treatment of malaria [63]. Galipealongiflora tree bark contains molecules with quinolines skeleton that are used as antileishmanial agents [64]. Cryptolepineis (an indoloquinoline alkaloid), dynemicin A, and streptonigrin, are naturally occurring antitumor antibiotics [65,66]. Synthetically accessed quinoline derivatives have shown antileishmanial [67,68], DNA binding agents [68], anticancer [69,70,71,72], antimycobacterial [73,74,75], antimicrobacterial [76], anticonvulsant [77], anti-inflammatory [78,79], and cardiovascular activities [80,81].
Towards discovering new compounds for MAO and AChE enzymes inhibition, herein we are reporting the synthesis, structure elucidation, molecular modeling, and enzyme inhibition of novel S-alkyl phthalimide- and S-benzyl-oxadiazole-quinoline hybrids.

2. Results and Discussion

2.1. Chemistry

S-alkyl phthalimide- and S-benzyl-oxadiazole-quinoline hybrids (5a–f and 6a–d) were synthesized following an optimized reported procedure [82,83,84]. The synthesis was initiated by the esterification of 2-phenylquinoline-4-carboxylic acid (1) in methanol using a catalytic amount of sulfuric acid, giving methyl 2-phenylquinoline-4-carboxylate (2). Compound 2 was hydrozinolyzed in methanol with hydrazine hydrate at reflux, pursued by cyclization utilizing potassium hydroxide in methanol at reflux and then acidification at room temperature to obtain 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4). The synthetic protocol is bifurcated here. On one side, 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) reacted with bromoalkyl substituted phthalimides to provide quinoline-oxadiazole-phthalimide hybrids 5a–f, and on the other side, compound 4 reacted with substituted benzyl bromides to provide 6a–d in excellent yields (Scheme 1).
The target molecules 5a–f and 6a–d were purified by recrystallization, and the structures of novel molecules were authenticated with the help of complementary analytical tools, including 13C-NMR, 1H-NMR, and FT-IR spectroscopic techniques (Figure S1). Compound 5a’s 1H-NMR analysis revealed typical peaks in the aromatic and aliphatic areas. The singlet for the two protons at δ = 5.54 ppm represented methylene proton (S-CH2-N) surrounded by sulfur and nitrogen atoms. In compounds 5b–f, a triplet for the methylene protons of the S-CH2 group was found between δ = 3.45 and δ = 3.26 ppm, whereas the methylene protons of N-CH2 were found between δ = 3.77 and δ = 3.56 ppm. The methylene groups between N-CH2 and S-CH2 of compounds 5c–f ranged from δ = 2.19 to δ = 1.32 ppm.
The protons present in the benzylic S-CH2 group of compounds 6a–d were observed as a singlet that ranged from δ = 4.69 to δ = 4.85 ppm. The singlet for one proton on the adjacent carbon atoms of the quinoline ring was observed between δ = 8.65 and δ = 8.06 ppm. All the protons present in the aromatic rings of the quinoline and phthalimide in compounds 5a–f were found in the range of δ 9.05–7.13 ppm, whereas aromatic protons present in the aromatic ring of quinoline and S-benzyl in compounds 6a–d were observed in the range of δ 9.05–7.35 ppm.
Similarly, 13C NMR of compounds 5a–f and 6a–d showed peaks for relevant carbon atoms at appropriate positions. Carbon atoms present in the carbonyl group of phthalimide moiety in compounds 5a–f were observed above δ 164 ppm. The carbon atoms OCN and SCN of the 1,3,4-oxadiazole in compounds 5a–f and 6a–d ring were observed between δ 164 and δ 155 ppm. All the carbon atoms present in the aromatic rings were found in the range of δ 149–118 ppm. The bridging carbon atom (SCN) present in 5a was observed at δ 39.13 ppm. The two bridging carbon atoms (SCCN) present between S and N atoms in compound 5b were observed at δ 37.13 and 30.14 ppm. The carbon atoms linked to the N atom were found in the range of δ 38–35 ppm. The carbon atoms linked to S atom were found in the range of δ 32–30 ppm. Other carbon atoms of the alkyl chain between N and S atoms in 5c–f were observed below δ 30 ppm. The benzylic carbon of compounds 6a–d was observed between δ 35.98 and δ 33.51 ppm.

2.2. Inhibitory Activity and SAR

In the synthesized compounds, the oxadiazole ring was substituted with quinoline on the left side. Besides, the oxadiazole ring was replaced with an isoindoline on the right side. The position of different functional groups on the basic pharmacophore ((2-phenylquinolin-4-yl)-1,3,4-oxadiazol-2-yl)) ring was studied to get specific information about the identification and selectivity of compounds to inhibit MAOs and AChE enzymes. Two series of compounds (5a–f and 6a–d) showed activity in low μM to nM ranges on the inhibition of MAOs and AChE enzymes (Table 1). Clorgyline and deprenyl were utilized as reference ligands for MAO-A and MAO-B, respectively. At the same time, donepezil was utilized as a positive AChE control. Compounds 5a and 5f showed activity in submicromolar ranges against MAO-A and MAO-B (IC50 = 0.91 ± 0.15 and 0.84 ± 0.06 μM, respectively). For AChE enzyme inhibition, compound 5c demonstrated the most active compound (IC50 = 1.02 ± 0.65 μM).
As the length of the carbon chain increases between the oxadiazole ring and isoindoline, activity toward MAO-A decreases as 5b, 5c, 5d, 5e, and 5f with values of 1.81 ± 0.38, 3.31 ± 0.80, 3.18 ± 1.23, 4.14 ± 0.35, and 4.88 ± 1.75 μM, respectively. In addition, when the isoindoline ring was replaced by a phenyl ring with different substitution CF3 at the ortho, para, and meta positions (6c, 6b, and 6a), the activity toward MAO-A increased by 6.81 ± 2.65, 1.51 ± 0.52, and 1.02 ± 0.92 μM, respectively.
By increasing the length of the carbon chain, activity toward MAO-B decreases as 5a, 5b, 5c, 5d, and 5e with values of 1.59 ± 1.66, 2.61 ± 2.48, 3.39 ± 0.42, 3.76 ± 1.04, and 3.84 ± 0.91 μM, respectively. While in the case of long carbon chain 5f, inhibition toward MAO-B was 0.84 ± 0.06 μM. Besides, when the isoindoline ring is replaced by a phenyl ring with different CF3 substitution at the ortho, para, and meta position (6a–c), the activity toward MAO-B increases with values of 5.59 ± 3.22, 3.71 ± 2.88, and 2.71 ± 0.88 μM, respectively.
Toward AChE inhibition, as the length of the carbon chain increases, the inhibition activity decreases as 5a, 5c, 5e, 5b, 5d, and 5f with IC50 values of 1.40 ± 0.45, 1.02 ± 0.65, 1.29 ± 0.75, 2.55 ± 0.96, 2.38 ± 0.92, and 3.32 ± 0.45 μM, respectively. While, by the replacing of the isoindoline ring by a phenyl ring with different substitution CF3 at the ortho, meta, and para position (6c, 6b, and 6a, respectively), the activity toward AChE increases 4.38± 1.45, 3.54 ± 1.05, and 3.23 ± 0.95 μM, respectively.
The correlation of newly synthesized (2-phenylquinolin-4-yl)-1,3,4-oxadiazol isoindoline-1,3-dione) with previously known MAO and AChE inhibitors was investigated. It seemed that the synthesized compounds showed higher inhibition activity toward targeted enzymes compared to the reported ones (Figure 2) [85,86]. Moreover, the synthesized compounds showed dual and multi-targeted inhibition.

2.3. Kinetic Studies

To determine the method of targeting MAO-A, MAO-B, and AChE enzymes, kinetic experiments for the most potent molecules (5a, 5f, and 5c) were carried out (Figure 3). Different test chemicals and substrate concentrations were utilized in the kinetic experiments. Lineweaver-Burk plots were employed to determine the kind of inhibition, and they were used to track how the inhibitor affected Km and Vmax by plotting the reciprocal reaction rate against the reciprocal substrate concentrations. As depicted in Figure 3, the investigated molecules displayed a pure competitive type of inhibition as the Vmax of enzymes was unaffected by differing doses of the test compounds while the Km increased.

2.4. Docking Studies

To investigate the docking pose of the most promising molecules with the binding pocket of the targeted enzymes, molecular docking predictions were executed. The assessment of the AutoDock4.2.6 software with the utilized settings was first carried out in accordance with the accessible experimental data. The co-crystallized ligands –namely, harmine, safinamide, and donepezil– with the MAO-A, MAO-B, and AChE were re-docked and compared to the experimentally resolved structures (PDB codes: 2Z5X, 2V5Z, and 4EY7, respectively) (Figure 4). As depicted in Figure 4, the portended docking poses resembled the native structures, having 0.23, 0.27, and 0.24 Å RMSD in relation to the co-crystallized conformations of harmine, safinamide, and donepezil, respectively (Figure 4). Summing up, the employed docking protocol would be utilized to predict the correct docking pose of inhibitors with the targeted enzymes.
Utilizing the docking protocol, the binding scores and modes of 5a, 5f, and 5c with MAO-A, MAO-B, and AChE enzymes, respectively, were anticipated (Figure 5). As illustrated in Figure 5, the investigated compounds demonstrated good inhibition affinity toward the inspected enzymes, with docking scores of –11.6, –15.3, and –14.0 kcal/mol with MAO-A, MAO-B, and AChE, respectively. The monitored possibility of inspected compounds towards MAO-A, MAO-B, and AChE might be ascribed to their capacity to exhibit numerous H-bonds, hydrophobic, vdW, and π-based interactions with the substantial residues within the binding pockets of these enzymes.
When the results were compared with the co-crystallized conformations of harmine, safinamide, and donepezil, many common interactions were observed (Figure 5). The presence of a quinoline ring formed the π-alkyl interactions with ILE180, LEU337, ILE335, LEU164, and ILE316 amino acids (Figure 5). Similarly, the 1,3,4-oxadiazol and isoindoline-,3-dione ring exhibited hydrogen bond, π-π stacked, and π-amide interactions with ASN141, TYR435, TYR124, TYR405, TYR398, TYR337, and TYR341 (Figure 5).

2.5. Drug-Like and ADMET Characteristics

The drug-like and ADMET features of the potent molecules were computed and compared with clorgyline, deprenyl, and donepezil as controls (Table 2). A compound’s hydrophilicity is indicated by Log P; if the value is negative, the compound is hydrophilic. All of the compounds in Table 2 are lipophilic. The total number of OH and NH atoms equals the nHBD, while the total number of N and O atoms resembles the nHBA. As listed in Table 2, the nHBA and nHBD are in the optimal ranges (nHBD < 5 and nHBA < 10). The ideal lipophilicity for BBB penetration for medications having CNS activity is a Log D ≤ 2. A Log D of more than 4 is considered as not suitable for a CNS medication. In vivo intestinal medication absorption is demonstrated by CaCo-2 permeability values. The ideal range of values should be more than −5.15 Log unit. All compounds showed normal values of CaCo-2 permeability. The higher HIA value, the higher intestinal absorption will be. All studied molecules pointed out an appropriate HIA value compared to the controls. Because of their lipophilic nature, all of our compounds can cross BBB. In metabolism and excretion, all investigated compounds were inhibitors of CYP2C19 (Table 2). A drug’s bodily clearance rate is categorized as high (>15), moderate (5–15), or low (<5). All the newly synthesized compounds had a low clearance rate. The AMES toxicity was evaluated. All compounds manifested low toxicity. Therefore, it can be suggested that all potent derivatives have a good ADMET profile compared to the controls. Further investigation is required to improve the toxicity profile of compounds.

2.6. Density Function Theory (DFT) Calculations

Further insight into the features of the investigated compounds was traced using a plethora of quantum mechanical calculations. In the first place, geometrical optimization was executed at the B3LYP/6-31G level of theory, and the obtained structures are illustrated in Figure 6. Afterwards, frequency computations were exerted, outlining that the optimized structures were true minima with no observable imaginary frequency values. Upon the optimized compounds, single-point energy and Frontier molecular orbitals (FMO) calculations were performed, and the global reactivity parameters were evaluated. Diagrams of HOMO and LUMO distributions are displayed in Figure 7. Table 3 enrolls energies of the optimized compounds (Eopt), the highest occupied molecular orbital (EHOMO), and the lowest unoccupied molecular orbital (ELUMO), along with the energy gap (Egap), global hardness (ƞ), global softness (σ), polarizability (α), and dipole moment (μ) of the studied compounds.
In the context of FMO theory, the molecule with less and high negative values of EHOMO and ELUMO, respectively, had superior nucleophilic nature. For ∆Egap, less positive values ensured the noticeable ability of the inspected compound to donate electrons.
The most reactive compound would be the one that has the smallest energy gap. The most kinetically stable compound showed a more favorable energy gap compared to the others. As evident in Figure 7, HOMO and LUMO distributions were noticed with lower and higher concentrations, respectively, around the phthalimide group in 5a–f compounds. While both distributions were found over the 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) in the 6a–d compounds.
According to data listed in Table 3, compound 5a would be highly reactive with favorable nucleophilic nature. This observation could be ascribed to the least negative EHOMO (–0.221 eV), highest negative ELUMO (–0.112 eV), and least positive Egap (0.108 eV) values. In comparison, the reversed affirmations were generally noticed in the case of compound 6d, which in turn was addressed as the most kinetically stable compound. The computed values of the global reactivity parameters ensured the FMO affirmations.

3. Experimental

3.1. Materials and Apparatus

All commercially obtained chemicals and reagents were employed to accomplish the targeted synthesis. Solvents of analytical grade were employed as provided. Uncorrected melting points were evaluated in open capillaries by a Gallenkamp melting point instrument (MP-D). Thin-layer chromatography was employed to analyze all the reactions. It was executed on Merck pre-coated plates (silica gel 60 F254, 0.25 mm), and was used to visualize the reactions utilizing fluorescence quenching under UV light (254 nm). A Bruker AV-300 spectrometer was applied to measure the 1H-NMR and 13C-NMR spectra (300 MHz). ATR was used to record IR spectra on a Shimadzu Fourier Transform Infrared spectrophotometer model (Attenuated Total Reflectance).

3.2. General Procedure

A modified multistep synthetic procedure was followed to access 5a–f and 6a–d.
In a typical experimental procedure, 2-phenylquinoline-4-carboxylic acid (1) (30 mmol) was esterified in 20 mL of methanol using catalytic amounts of sulfuric acid (0.5 mL) at reflux temperature for 4 h. The mixture was neutralized with 50 mL of saturated NaHCO3 solution and extracted three times with 30 mL of ethyl acetate. The organic phase was filtered after being dried over anhydrous sodium sulfate. The solvent was then extracted to get crude methyl 2-phenylquinoline-4-carboxylate in quantitative yield.
Methyl 2-phenylquinoline-4-carboxylate (2) (25 mmol) was dissolved in 30 mL of CH3OH, and NH2NH2.H2O (80%, 0.06 mol) was inserted dropwise. The reaction mixture was cooled to room temperature and then poured into ice-cold water after 8 h of refluxing. We precipitated, filtered, dried, and recrystallized 2-phenylquinoline-4-carbohydrazide (3) from methanol.
A solution of 2-phenylquinoline-4-carbohydrazide (3) (20 mmol) in 10 mL of methanol and 3 equivalent KOH dissolved in 30 mL of methanol was inserted. After 10 min, carbon disulfide (30 mmol) was slowly inserted, and the whole reaction mixture was subjected to reflux for 12 h. The reaction mixture was concentrated, brought to room temperature, and then added to ice water. With dilute HCl, the pH of the solution was brought down to 2. Warm water was used to wash the precipitated 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) before it was recrystallized from methanol.
Acetone was used to dissolve 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) (3 mmol), and potassium carbonate (4 mmol) was added. N-bromoalkylphthalimide (4 mmol) was added to the reaction mixture after it had been agitated at room temperature for 10 min. The reaction mixture was then mixed once more at room temperature for 6 h. To obtain pure 5a–f, the crude was recrystallized from methanol after the solvent was removed.
Acetone was utilized to dissolve 5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazole-2-thiol (4) (3 mmol), and potassium carbonate (4 mmol) was added. Substituted benzyl bromide (4mmol) was added to the reaction mixture after it had been agitated at room temperature for 10 min. The reaction mixture was then mixed once more at room temperature for 6 h. To get pure 6a–d, the crude was recrystallized from methanol.

3.2.1. 2-((5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)methyl)isoindoline-1,3-dione (5a)

Pharmaceuticals 16 00011 i001
Off white solid; yield: 66%, Rf: 0.72 (Chloroform: acetone, 9:1); mp:178–180 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm); 9.05 (d, J = 9 Hz, 1H), 8.65 (s, 1H), 8.39 (d, J = 9 Hz, 2H), 8.20 (d, J = 9 Hz, 1H), 7.84 (m, 6H), 7.62 (m, 3H), 5.54 (s, 2H);13C NMR (75 MHz, DMSO-d6); 166.98, 164.88, 163.09, 156.34, 148.74, 138.12, 135.40, 131.87, 131.24, 130.69, 130.53, 129.49, 128.95, 128.55, 127.26, 123.95, 122.36, 118.91 39.13; FT-IR υ (cm−1): 3006 (C-H, SP2), 2930 (C-H, SP3), 1717 (C = O), 1614, 1595 (C = N); HR/MS (EI): m/z calculated for C26H16N4O3S: 464.0943; found 464.0947.

3.2.2. 2-(2-(5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)ethyl)isoindoline-1,3-dione (5b)

Pharmaceuticals 16 00011 i002
Off white solid; yield: 83%, Rf: 0.76 (Chloroform: acetone, 9:1); mp:198–200 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm); 8.46 (d, J = 9 Hz, 1H), 8.06 (s, 1H), 7.92 (d, J = 6 Hz, 2H), 7.72 (d, J = 9 Hz, 1H), 7.45 (t, J = 15 Hz, 1H), 7.26 (m, 5H), 7.139d, J = 6 Hz, 3H), 3.66 (t, J = 12 Hz, 2H), 3.26 (t, J = 12 Hz, 2H); 13C NMR (75 MHz, DMSO-d6); 167.65, 164.63, 163.46, 155.83, 148.27, 137.66, 134.39, 131.38, 130.73, 130.17, 130.03, 128.99, 128.40, 127.90, 127.38, 125.52, 123.00, 121.81, 118.17.37.13, 30.54; FT-IR υ (cm−1): 3055 (C-H, SP2), 2942 (C-H, SP3), 1714 (C = O), 1594, 1525 (C = N); HR/MS (EI): m/z calculated for C27H18N4O3S: 478.5218; found 478.5220.

3.2.3. 2-(3-(5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)propyl)isoindoline-1,3-dione (5c)

Pharmaceuticals 16 00011 i003
Off white solid; yield: 80%, Rf: 0.77 (Chloroform: acetone, 9:1); mp: 154–158 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm); 8.98 (d, J = 9 Hz, 1H), 8.51(s, 1H), 8.31 (d, J = Hz, 2H), 8.18 (d, J = 9 Hz, 1H), 7.81 (m, 6H), 7.55 (d, J = 6 HZ, 3H), 3.77 (t, J = 15 Hz, 2H), 3.45 (t, J = 12 Hz, 2H), 2.19 (t, J = 12 Hz, 2H); 13C NMR (75 MHz, DMSO-d6); 168.56, 165.50, 164.07, 146.28, 148.75, 138.10, 134.76, 132.19, 131.18, 130.60, 130.49, 129.44, 128.83, 128.64, 127.78, 126.02, 123.44, 122.38, 118.66, 36.64, 30.14, 28.; FT-IR υ (cm−1): 3047 (C-H, SP2), 2943 (C-H, SP3), 1702 (C = O), 1599, 1536 (C = N); HR/MS (EI): m/z calculated for C29H22N4O3S: 492.5484; found 492.5487.

3.2.4. 2-(4-(5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)butyl)isoindoline-1,3-dione (5d)

Pharmaceuticals 16 00011 i004
White solid; yield: 86%, Rf: 0.76 (Chloroform: acetone, 9:1); mp: 121–125 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm); 8.97 (d, J = 9 Hz, 1H), 8.48 (s, 1H), 8.30 (d, J = 6 Hz, 2H), 8.17 (d, J = 9 Hz, 1H), 7.89 (t, J = 15 Hz, 1H), 7.77 (m, 5H), 7.56 (d, J = 9 Hz, 3H), 3.64 (t, J = 9 Hz, 2H), 3.42 (t, J = 9 Hz, 2H), 1.78 (m, 4H); 13C NMR (75 MHz, DMSO-d6); 168.43, 165.52, 164.00, 156.26, 148.75, 138.11, 134.75, 132.02, 131.16, 130.58, 130.48, 129.44, 128.81, 128.62, 127.75, 126.04, 123.40, 122.36, 118.62, 37.31, 32.13, 27.33, 26.82; FT-IR υ (cm−1): 3040 (C-H, SP2), 2943 (C-H, SP3), 1707 (C = O), 1598, 1549 (C = N); HR/MS (EI): m/z calculated for C28H20N4O3S: 506.1413; found 506.1416.

3.2.5. 2-(5-(5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)pentyl)isoindoline-1,3-dione (5e)

Pharmaceuticals 16 00011 i005
White solid; yield 74%, Rf: 0.67 (Chloroform: acetone, 9:1); mp: 146–150 °C; 1H-NMR (30 0MHz, DMSO-d6): δ (ppm); 8.99 (d, J = 6 Hz, 1H), 8.49 (s, 1H), 8.29 (d, J = 6 Hz, 2H), 8.17 (j = 9 Hz, 1H), 7.88 (t, J = 15 Hz, 1H), 7.75 (m, 5H), 3.58 (t, J = 15 Hz, 2H), 3.38 (t, J = 18 Hz, 2H), 1.88 (pnt, J = 15, 9 Hz, 2H), 1.64 (m, 2H), 1.47 (t, J = 15 Hz, 2H);13C NMR (75 MHz, DMSO-d6); 168.39, 165.59, 163.98, 156.27, 148.76, 138.11, 134.77, 132.00, 131.15, 130.57, 130.48, 129.43, 128.79, 128.67, 127.73, 126.04, 123.40, 122.38, 118.62, 37.64, 32.35, 28.98, 27.88, 25.64; FT-IR υ (cm−1): 3060 (C-H, SP2), 2933 (C-H, SP3), 1713 (C = O), 1597, 1534 (C = N); HR/MS (EI): m/z calculated for C30H24N4O3S: 520.1569; found 520.1572.

3.2.6. 2-(6-(5-(2-Phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ylthio)hexyl)isoindoline-1,3-dione (5f)

Pharmaceuticals 16 00011 i006
White solid; yield 73%, Rf: 0.85 (Chloroform: acetone, 9:1); mp: 132–135 °C; 1H-NMR (300 MHz, DMSO-d6): δ (ppm); 8.97(d, J = 9 Hz, 1H), 8.48 (s, 1H), 8.29 (t, J = 9 Hz, 2H), 8.16 (d, J = 9 Hz, 1H), 7.88 (t, J = 12 Hz, 1H), 7.77 (m, 5H), 7.56 (m, 3H), 3.56 (t, J = 18 Hz, 2H), 3.37 (t, J = 15 Hz, 2H), 1.81 (pnt, J = 12, 6 Hz, 2H), 1.59 (pnt, J = 15, 9 Hz, 2H), 1.46 (pnt, J = 18, 9 Hz, 2H), 1.32 (pnt, J = 15, 6 Hz, 2H); 13C NMR (75 MHz, DMSO-d6); 168.38, 165.68, 163.98, 156.28, 148.76, 138.11, 134.77, 132.02, 131.17, 130.60, 130.49, 129.44, 128.82, 128.69, 127.74, 126.03, 123.40, 122.39, 118.65, 37.70, 32.43, 29.26, 28.22, 27.88, 26.12; FT-IR υ (cm−1): 30,457 (C-H, SP2), 2933 (C-H, SP3), 1717 (C = O), 1596, 1536 (C = N); HR/MS (EI): m/z calculated for C31H26N4O3S: 534.1726; found 534.1728.

3.2.7. 4-(5-(4-(Trifluoromethyl)benzylthio)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline (6a)

Pharmaceuticals 16 00011 i007
White solid; yield: 74%, Rf: 0.84 (n-hexane: ethylacetate; 6:4); mp: 144–145 °C; 1H-NMR (300 MHz, CDCl3): δ (ppm); 9.14 (d, J = 9 Hz, 1H), 8.38 (s, 1H), 8.23 (m, 3H), 7.84 (m, 1H), 7.70 (m, 5H), 7.55 (m, 3H), 4.65 (s, 2H); 13C NMR (75 MHz, CDCl3); 164.66, 164.53, 156.74, 149.19, 139.71, 138.60, 130.66, 130.52, 130.47,130.22, 129.92, 129.61, 129.02, 128.27, 128.18, 127.46, 125.89, 125.85, 125.80, 122.44, 122.11, 118.32, 35.98; FT-IR υ (cm−1): 3064 (C-H, SP2), 2950 (C-H, SP3), 1599 (C = N), 1325 (C-S); HR/MS (EI): m/z calculated for C25H16F3N3OS: 463.0966; found 463.0969.

3.2.8. 4-(5-(3-(Trifluoromethyl)benzylthio)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline (6b)

Pharmaceuticals 16 00011 i008
White solid; yield: 76%, Rf: 0.64 (n-hexane: ethylacetate; 6:4); mp: 134–135 °C; 1H-NMR (300 MHz, CDCl3): δ (ppm); 8.97 (d, J = 9 Hz, 1H), 8.48 (s, 1H), 8.29 (dd, J 9, 6 Hz, 2H), 8.17 (d, J = 9 Hz, 1H), 7.95 (s, 1H), 7.86 (dd, J = 15, 6 Hz, 2H), 7.74 (m, 1H), 7.59 (m, 5H), 4.78 (s, 2H); 13C NMR (75 MHz, CDCl3; 164.84, 164.35, 156.25, 148.74, 139.55, 138.99, 138.06, 133.77, 131.17, 130.61, 130.49, 130.12, 129.88, 129.42, 128.84, 128.50, 127.73, 126.32, 126.20, 125.98, 124.97, 124.92, 122.71, 122.31.118.65, 35.48; FT-IR υ (cm−1): 3054 (C-H, SP2), 2951 (C-H, SP3), 1595 (C = N), 1327 (C-S); HR/MS (EI): m/z calculated for C25H16F3N3OS: 463.0966; found 463.0968.

3.2.9. 4-(5-(2-(Trifluoromethyl)benzylthio)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline (6c)

Pharmaceuticals 16 00011 i009
White solid; yield: 76%, Rf: 0.81 (n-hexane: ethylacetate; 6:4); mp: 122–123 °C; 1H-NMR (300 MHz, CDCl3): δ (ppm); 8.98 (d, J = 9 Hz, 1H), 8.45 (s, 1H), 8.28 (m, 2H), 8.17 (d, J = 6 Hz, 1H), 7.89 (m, 2H), 7.73 (m, 3H), 7.56 (m, 4H), 4.85 (s, 2H); 13C NMR (75 MHz, CDCl3; 164.45, 164.42, 156.23, 148.75, 138.05, 134.69, 133.60, 132.52, 131.20, 130.63, 130.50, 129.44, 129.29, 128.87, 128.50, 127.88, 128.50, 127.88, 127.70, 127.48, 126.93, 126.86, 126.57, 125.96, 122.33, 33.51; FT-IR υ (cm−1): 3065 (C-H, SP2), 2950 (C-H, SP3), 1599 (C = N), 1346 (C-S); HR/MS (EI): m/z calculated for C25H16F3N3OS: 463.0966; found 463.0970.

3.2.10. 4-(5-(Benzylthio)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline (6d)

Pharmaceuticals 16 00011 i010
White solid; yield: 74%, Rf: 0.85 (n-hexane: ethylacetate; 6:4); mp: 139–140 °C; 1H-NMR (300 MHz, DMS0-d6): δ (ppm); 8.98 (d, J = 9 Hz, 1H), 8.46 (s, 1H), 8.29 (d, J = 6 Hz, 2H), 8.16 (d, J = 6 Hz, 1H), 7.88 (t, J = 15 Hz, 1H), 7.75 (t, J = 15 Hz, 1H), 7.58 (m, 5H), 7.35 (m, 3H), 4.69 (s, 2H);13C NMR (75 MHz, DMS0-d6; 165.09, 164.21, 156.26, 148.75, 138.08, 137.04, 131.18, 130.63, 130.49, 129.59, 129.45, 129.10, 128.86, 128.52, 128.30, 127.75, 126.01, 122.32, 118.63, 36.28; FT-IR υ (cm−1): 3062 (C-H, SP2), 2950 (C-H, SP3), 1595 (C = N), 1336 (C-S); HR/MS (EI): m/z calculated for C24H17F3N3OS: 395.1092; found 395.1095.

3.3. Inhibition Assay Protocol

3.3.1. Monoamine Oxidase

According to the previously reported protocol, the synthesized compounds’ action on the monoamine oxidase (MAO-A and MAO-B) enzymes was tested. The enzyme was produced just 15 to 20 min before, at a cold room temperature. Accordingly, clorgyline (60 nM) or deprenyl (300 nM) were used to permanently inhibit MAO-A and MAO-B activity. White 96-well plates were utilized for the test. The assay volume was 100 μL, having 60 μL buffer (pH 7.4) and 10 μL test compound (0.1 mM, 10% DMSO), followed by adding enzyme 10 μL (26 μg of protein for MAO-A and 5.0 μg for MAO-B). For MAO-A and MAO-B, the mixture was incubated for 20 and 15 min, respectively. The mixture was then given 10 μL of the substrate and 10 μL of newly prepared Amplex red. Accordingly, the final concentrations of clorgyline and deprenyl were utilized to calculate the activities of non-MAO-A and MAO-B. Using a fluorescence plate reader (BMG Labtech GmbH, orten berg Germany), the change in fluorescence was identified. The compounds that showed inhibition of either MAO-A or MAO-B activity of >50% underwent additional testing to determine their IC50 values. The non-linear curve fitting tool PRISM 5.0 (GraphPad, San Diego, CA, USA) was employed to compute IC50 values.

3.3.2. Acetylcholinesterase

All substances were put through a little modified version of Ellman’s test to gauge the effectiveness of their ability to inhibit acetylcholinesterase (AChE). Released thiocholine reacts with chromogenic reagent 5,5-dithio-bis (2-nitrobenzoic) acid to produce a colorful product (DTNB). At a concentration of 2.5 units/mL, the enzyme solutions were prepared. The assay volume was 100 μL, having 60 μL buffer and 10 μL test compound (0.1 mM, 10% DMSO), pursued by inserting enzyme 10 μL (0.04 U/well). The mixture was incubated for 10 min. 10 μL of the substrate and 10 μL of DTNB were added to the mixture. After 30 min, the production of the yellow anion was recorded at 405 nm.

3.4. Molecular Docking and ADMET Characteristics

3.4.1. Enzyme Preparation

The X-ray structures of MAO-A (PDB code: 2Z5X [87]), MAO-B (PDB code: 2V5Z [88]), and AChE (PDB code: 4EY7 [89]) were opted as templates for all docking predictions. The enzymes were prepared by excluding all ions, heteroatoms, water molecules, and ligands. The Modeller software was applied to create all missing residues [90]. The investigated enzymes’ protonation states were examined using the H++ website [91]. All missing hydrogen atoms were inserted.

3.4.2. Inhibitor Preparation

The 3D molecular structures of the inspected molecules 5a–f and 6a–d were manually constructed. Before any computation, all investigated compounds were firstly minimized using the MMFF94S force field implemented inside the SZYBKI software [92,93]. The charges of all investigated compounds were computed utilizing the Gasteiger-Marsili method [94].

3.4.3. Docking Calculations

The AutoDock4.2.6 software was employed to execute all docking computations [95]. Based on the AutoDock protocol, the pdbqt file for the examined enzymes was generated utilizing the MGL (molecular graphics laboratory) tools 1.5.7 [96]. In general, the docking parameters of the AutoDock4.2.6 software were maintained at their default settings. The GA (number of genetic algorithms) run variables was 250. The eval (maximum number of energy evaluations) was 25,000,000. The grid box size was 50 Å × 50 Å × 50 Å. For all docking engines, the cartesian coordinates of the grid center were located at the center of the binding pockets of the investigated enzymes. The AutoGrid4.2.6 program was used to create the grid maps with a spacing of 0.375 Å. All molecular interactions were visualized by the Discovery Studio module of Biovia software [97].

3.4.4. ADMET Properties

For the purpose of identifying significant compounds that exhibit drug-likeness for current in silico studies, excellent and better experimental ADMET (absorption, distribution, metabolism, excretion, and toxicity) features are required. The physicochemical properties of the compounds under study, including MW, nHBA, nHBD, and Log P were estimated. Moreover, the properties in accordance with absorption and distribution included volume of distribution, HIA, Caco2 permeability, and BBB. Metabolism-associated properties were estimated using CYP2C19 inhibitor. Excretion included clearance. Toxicity was evaluated based on AMES toxicity. All the parameters were computed using the online server ADMET lab 2.0 [98].

3.5. DFT Studies

To thoroughly investigate the molecular structures of the molecules under study, density functional theory (DFT) calculations were executed at the B3LYP/6-31G level using Gaussian09 software [99]. The geometries of the studied compounds were first optimized and further submitted to frequency computations to ensure if the obtained structures were true minima or not. The distributions and energies of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) were unveiled by means of the Frontier molecular orbitals (FMO). To well-characterize the features of the studied compounds, a diversity of global reactivity descriptors, including global hardness (ƞ), global softness (σ), polarizability (α), and dipole moment (μ), was assessed.

4. Conclusions

A series of 2-methyl-5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazole were synthesized with various substituents and analyzed against monoamine oxidase (MAO-A and MAO-B) and acetylcholinesterase (AChE) enzymes. All molecules showed promising inhibition in the lower μM range against targeted enzymes. Compounds 5a and 5f were the most promising MAO-A and MAO-B inhibitors (IC50 = 0.91 ± 0.15 and 0.84 ± 0.06 nM, respectively). While compound 5c exhibited the most efficient acetylcholinesterase inhibition (IC50 = 1.02 ± 0.65 μM). Furthermore, 5a–f and 6a–d were in silico investigated towards MAO-A, MAO-B, and AChE as anti-Alzheimer treatments using the AutoDock4.2.6 software. According to docking scores results, 5a, 5f, and 5c demonstrated the promising docking scores against the investigated enzymes. Moreover, the crucial function played by the investigated enzymes in Alzheimer’s remediation proposes that promising molecules may act as potent novel chemical entities in identifying multi-target-directed inhibitors.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ph16010011/s1, Figure S1: 1H-NMR, 13C-NMR, and FT-IR Spectra of compounds 5a–f and 6a–d.

Author Contributions

Conceptualization, B.A.K.; data curation, S.S.H., J.I., S.J. and S.A.E.; formal analysis, S.S.H., J.I. and S.A.E.; investigation, B.A.K., S.J., S.A.E. and P.A.S.; methodology, B.A.K. and P.A.S.; project administration, B.A.K. and P.A.S.; resources, B.A.K. and A.M.S.; software, S.S.H. and M.A.A.I.; supervision, B.A.K.; visualization, S.A.E. and P.A.S.; writing—original draft, S.S.H., S.J., S.A.E. and P.A.S.; writing—review and editing, B.A.K., J.I., G.A.G., A.M.S., A.M.A. and M.A.A.I. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the Supplementary Material.

Acknowledgments

B.A.K. thanks the Higher Education Commission (HEC) of Pakistan for providing finance to conduct the synthesis under the National Research Program for Universities (NRPU grant # 6455). J.I. gratefully acknowledges the financial support for this research provided by the Higher Education Commission of Pakistan (HEC) via NRPU project No. 20-15846/NRPU/R&D/HEC/2021, German-Pakistani Research Collaboration Programme and Equipment Grant funded by DAAD, Germany. Ahmed M. Shawky would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: 22UQU4331174DSR06.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Saez-Atienzar, S.; Masliah, E. Author Correction: Cellular senescence and Alzheimer disease: The egg and the chicken scenario. Nat. Rev. Neurosci. 2020, 21, 587. [Google Scholar] [CrossRef] [PubMed]
  2. Alzheimer’s Disease International. From Plan to Impact: Progress towards Targets of the Global Action Plan on Dementia; Alzheimer’s Disease International: London, UK, 2018. [Google Scholar]
  3. Saxena, A.K. The Structural Hybrids of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease: A Review. Alzheimer’s Neurodegener. Dis. 2019, 4, 015. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Yanez, M.; Vina, D. Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease. Curr. Top. Med. Chem. 2013, 13, 1692–1706. [Google Scholar] [CrossRef] [PubMed]
  5. Carradori, S.; Silvestri, R. New Frontiers in Selective Human MAO-B Inhibitors. J. Med. Chem. 2015, 58, 6717–6732. [Google Scholar] [CrossRef]
  6. Kumar, B.; Sheetal, S.; Mantha, A.K.; Kumar, V. Recent developments on the structure-activity relationship studies of MAO inhibitors and their role in different neurological disorders. RSC Adv. 2016, 6, 42660–42683. [Google Scholar] [CrossRef]
  7. Yang, H.L.; Cai, P.; Liu, Q.H.; Yang, X.L.; Li, F.; Wang, J.; Wu, J.J.; Wang, X.B.; Kong, L.Y. Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-beta aggregation for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2017, 138, 715–728. [Google Scholar] [CrossRef]
  8. Thai, N.Q.; Nguyen, H.L.; Linh, H.Q.; Li, M.S. Protocol for fast screening of multi-target drug candidates: Application to Alzheimer’s disease. J. Mol. Graph. Model. 2017, 77, 121–129. [Google Scholar] [CrossRef]
  9. Blackard, W.G., Jr.; Sood, G.K.; Crowe, D.R.; Fallon, M.B. Tacrine. A cause of fatal hepatotoxicity? J. Clin. Gastroenterol. 1998, 26, 57–59. [Google Scholar] [CrossRef]
  10. Behl, T.; Kaur, D.; Sehgal, A.; Singh, S.; Sharma, N.; Zengin, G.; Andronie-Cioara, F.L.; Toma, M.M.; Bungau, S.; Bumbu, A.G. Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors. Molecules 2021, 26, 3724. [Google Scholar] [CrossRef]
  11. Kumar, B.; Kumar, V.; Prashar, V.; Saini, S.; Dwivedi, A.R.; Bajaj, B.; Mehta, D.; Parkash, J.; Kumar, V. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase. Eur. J. Med. Chem. 2019, 177, 221–234. [Google Scholar] [CrossRef]
  12. Vina, D.; Matos, M.J.; Yanez, M.; Santana, L.; Uriarte, E. 3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer’s disease. MedChemComm 2012, 3, 213–218. [Google Scholar] [CrossRef]
  13. Sterling, J.; Herzig, Y.; Goren, T.; Finkelstein, N.; Lerner, D.; Goldenberg, W.; Miskolczi, I.; Molnar, S.; Rantal, F.; Tamas, T.; et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer’s disease. J. Med. Chem. 2002, 45, 5260–5279. [Google Scholar] [CrossRef] [PubMed]
  14. Rullo, M.; Cipolloni, M.; Catto, M.; Colliva, C.; Miniero, D.V.; Latronico, T.; de Candia, M.; Benicchi, T.; Linusson, A.; Giacchè, N.; et al. Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies. J. Med. Chem. 2022, 65, 3962–3977. [Google Scholar] [CrossRef] [PubMed]
  15. Mousseau, D.D.; Baker, G.B. Recent developments in the regulation of monoamine oxidase form and function: Is the current model restricting our understanding of the breadth of contribution of monoamine oxidase to brain [dys] function? Curr. Top. Med. Chem. 2012, 12, 2163–2176. [Google Scholar] [CrossRef]
  16. Henchcliffe, C.; Schumacher, H.C.; Burgut, F.T. Recent advances in Parkinson’s disease therapy: Use of monoamine oxidase inhibitors. Expert Rev. Neurother. 2005, 5, 811–821. [Google Scholar] [CrossRef] [PubMed]
  17. Kaya Cavusoglu, B.; Saglik, B.N.; Ozkay, Y.; Inci, B.; Kaplancikli, Z.A. Design, synthesis, monoamine oxidase inhibition and docking studies of new dithiocarbamate derivatives bearing benzylamine moiety. Bioorg. Chem. 2018, 76, 177–187. [Google Scholar] [CrossRef] [PubMed]
  18. Li, Q.H.; Ding, Y.; Huang, N.W. Synthesis and biological activities of dithiocarbamates containing 1,2,3-triazoles group. Chin. Chem. Lett. 2014, 25, 1469–1472. [Google Scholar] [CrossRef]
  19. Knez, D.; Sova, M.; Kosak, U.; Gobec, S. Dual inhibitors of cholinesterases and monoamine oxidases for Alzheimer’s disease. Future Med. Chem. 2017, 9, 811–832. [Google Scholar] [CrossRef]
  20. Fu, J.; Bao, F.Q.; Gu, M.; Liu, J.; Zhang, Z.P.; Din, J.L.; Xi, S.S.; Ding, J.S. Design, synthesis and evaluation of quinolinone derivatives containing dithiocarbamate moiety as multifunctional AChE inhibitors for the treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. 2020, 35, 118–128. [Google Scholar] [CrossRef]
  21. Hassanzadeh, M.; Hassanzadeh, F.; Khodarahmi, G.A.; Rostami, M.; Azimi, F.; Nadri, H.; Moghadam, F.H. Design, synthesis, and bio-evaluation of new isoindoline-1,3-dione derivatives as possible inhibitors of acetylcholinesterase. Res. Pharm. Sci. 2021, 16, 482–492. [Google Scholar] [CrossRef]
  22. Karabeliov, V.R.; Kondeva-Burdina, M.S.; Vassilev, N.G.; Elena, K.; Angelova, V.T. Neuroprotective evaluation of novel substituted 1,3,4-oxadiazole and aroylhydrazone derivatives. Bioorg. Med. Chem. Lett. 2022, 59, 128516. [Google Scholar] [CrossRef] [PubMed]
  23. Rana, K.; Salahuddin; Sahu, J.K. Significance of 1,3,4-Oxadiazole Containing Compounds in New Drug Development. Curr. Drug Res. Rev. 2021, 13, 90–100. [Google Scholar] [CrossRef] [PubMed]
  24. Hkiri, S.; Hafidh, A.; Cavalier, J.F.; Touil, S.; Samarat, A. Design, synthesis, antimicrobial evaluation, and molecular docking studies of novel symmetrical 2,5-difunctionalized 1,3,4-oxadiazoles. J. Heterocycl. Chem. 2019, 57, 1044–1054. [Google Scholar] [CrossRef]
  25. Omar-Eldeen, H. Synthesis and Antimicrobial Evaluation of Some Bis-1,3,4-Butane-1-3, 4-Oxadiazole Derivatives. Ibn AL-Haitham J. Pure Appl. Sci. 2009, 22, 120–124. [Google Scholar]
  26. Şahin, G.; Palaska, E.; Ekizoğlu, M.; Özalp, M. Synthesis and antimicrobial activity of some 1,3,4-oxadiazole derivatives. Il Farmaco 2002, 57, 539–542. [Google Scholar] [CrossRef] [PubMed]
  27. Abdel, R.; Farghaly, A.H. Synthesis, Reactions and Antimicrobial Activity of Some New Indolyl-1,3,4-Oxadiazole, Triazole and Pyrazole Derivatives. J. Chin. Chem. Soc. 2004, 51, 147–156. [Google Scholar] [CrossRef]
  28. Almasirad, A.; Vousooghi, N.; Tabatabai, S.A.; Kebriaeezadeh, A.; Shafiee, A. Synthesis, Anticonvulsant and Muscle Relaxant Activities of Substituted 1,3,4-oxadiazole, 1,3,4-thiadiazole and 1,2,4-triazole. Acta Chim. Slov. 2007, 54, 317–324. [Google Scholar]
  29. Kashaw, S.K.; Gupta, V.; Kashaw, V.; Mishra, P.; Stables, J.P.; Jain, N.K. Anticonvulsant and sedative-hypnotic activity of some novel 3-[5-(4-substituted)phenyl-1,3,4-oxadiazole-2yl]-2-styrylquinazoline-4(3H)-ones. Med. Chem. Res. 2010, 19, 250–261. [Google Scholar] [CrossRef]
  30. Wang, S.; Liu, H.; Wang, X.; Lei, K.; Li, G.; Li, J.; Liu, R.; Quan, Z. Synthesis of 1,3,4-oxadiazole derivatives with anticonvulsant activity and their binding to the GABAA receptor. Eur. J. Med. Chem. 2020, 206, 112672. [Google Scholar] [CrossRef]
  31. Bhat, M.A.; Al-Omar, M.A.; Siddiqui, N. Synthesis, anticonvulsant and neurotoxicity of some novel 1,3,4-oxadiazole derivatives of phthalimide. Pharma Chem. 2010, 2, 1–10. [Google Scholar]
  32. Nazar, S.; Siddiqui, N.; Alam, O. Recent progress of 1,3,4-oxadiazoles as anticonvulsants: Future horizons. Arch. Pharm. 2020, 353, e1900342. [Google Scholar] [CrossRef] [PubMed]
  33. Glomb, T.; Szymankiewicz, K.; Swiatek, P. Anti-Cancer Activity of Derivatives of 1,3,4-Oxadiazole. Molecules 2018, 23, 3361. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Gudipati, R.; Anreddy, R.N.; Manda, S. Synthesis, characterization and anticancer activity of certain 3-{4-(5-mercapto-1,3,4-oxadiazole-2-yl)phenylimino}indolin-2-one derivatives. Saudi Pharm. J. 2011, 19, 153–158. [Google Scholar] [CrossRef] [PubMed]
  35. Valente, S.; Trisciuoglio, D.; De Luca, T.; Nebbioso, A.; Labella, D.; Lenoci, A.; Bigogno, C.; Dondio, G.; Miceli, M.; Brosch, G.; et al. 1,3,4-Oxadiazole-containing histone deacetylase inhibitors: Anticancer activities in cancer cells. J. Med. Chem. 2014, 57, 6259–6265. [Google Scholar] [CrossRef] [PubMed]
  36. Vaidya, A.; Pathak, D.; Shah, K. 1,3,4-oxadiazole and its derivatives: A review on recent progress in anticancer activities. Chem. Biol. Drug Des. 2021, 97, 572–591. [Google Scholar] [CrossRef]
  37. Bhutani, R.; Pathak, D.P.; Kapoor, G.; Husain, A.; Iqbal, M.A. Novel hybrids of benzothiazole-1,3,4-oxadiazole-4-thiazolidinone: Synthesis, in silico ADME study, molecular docking and in vivo anti-diabetic assessment. Bioorg. Chem. 2019, 83, 6–19. [Google Scholar] [CrossRef]
  38. Gani, R.S.; Kudva, A.K.; Timanagouda, K.; Raghuveer; Mujawar, S.B.H.; Joshi, S.D.; Raghu, S.V. Synthesis of novel 5-(2,5-bis(2,2,2-trifluoroethoxy)phenyl)-1,3,4-oxadiazole-2-thiol derivatives as potential glucosidase inhibitors. Bioorg. Chem. 2021, 114, 105046. [Google Scholar] [CrossRef]
  39. Hamdani, S.S.; Khan, B.A.; Ahmed, M.N.; Hameed, S.; Akhter, K.; Ayub, K.; Mahmood, T. Synthesis, crystal structures, computational studies and α-amylase inhibition of three novel 1,3,4-oxadiazole derivatives. J. Mol. Struct. 2020, 1200, 127085. [Google Scholar] [CrossRef]
  40. Khan, H.; Zafar, M.; Patel, S.; Shah, S.M.; Bishayee, A. Pharmacophore studies of 1,3,4-oxadiazole nucleus: Lead compounds as alpha-glucosidase inhibitors. Food Chem. Toxicol. 2019, 130, 207–218. [Google Scholar] [CrossRef]
  41. Gan, X.; Hu, D.; Chen, Z.; Wang, Y.; Song, B. Synthesis and antiviral evaluation of novel 1,3,4-oxadiazole/thiadiazole-chalcone conjugates. Bioorg. Med. Chem. Lett. 2017, 27, 4298–4301. [Google Scholar] [CrossRef]
  42. Peng, F.; Liu, T.; Wang, Q.; Liu, F.; Cao, X.; Yang, J.; Liu, L.; Xie, C.; Xue, W. Antibacterial and Antiviral Activities of 1,3,4-Oxadiazole Thioether 4H-Chromen-4-one Derivatives. J. Agric. Food Chem. 2021, 69, 11085–11094. [Google Scholar] [CrossRef] [PubMed]
  43. Gan, X.; Hu, D.; Li, P.; Wu, J.; Chen, X.; Xue, W.; Song, B. Design, synthesis, antiviral activity and three-dimensional quantitative structure-activity relationship study of novel 1,4-pentadien-3-one derivatives containing the 1,3,4-oxadiazole moiety. Pest Manag. Sci. 2016, 72, 534–543. [Google Scholar] [CrossRef] [PubMed]
  44. Wu, W.N.; Chen, Q.; Tai, A.Q.; Jiang, G.Q.; Ouyang, G.P. Synthesis and antiviral activity of 2-substituted methylthio-5-(4-amino-2-methylpyrimidin-5-yl)-1,3,4-oxadiazole derivatives. Bioorg. Med. Chem. Lett. 2015, 25, 2243–2246. [Google Scholar] [CrossRef] [PubMed]
  45. Wang, P.Y.; Shao, W.B.; Xue, H.T.; Fang, H.S.; Zhou, J.; Wu, Z.B.; Song, B.A.; Yang, S. Synthesis of novel 1,3,4-oxadiazole derivatives containing diamides as promising antibacterial and antiviral agents. Res. Chem. Intermed. 2017, 43, 6115–6130. [Google Scholar] [CrossRef]
  46. Akhtar, T.; Hameed, S.; Al-Masoudi, N.A.; Loddo, R.; La Colla, P. In vitro antitumor and antiviral activities of new benzothiazole and 1,3,4-oxadiazole-2-thione derivatives. Acta Pharm. 2008, 58, 135–149. [Google Scholar] [CrossRef] [Green Version]
  47. Omar, F.A.; Mahfouz, N.M.; Rahman, M.A. Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives. Eur. J. Med. Chem. 1996, 31, 819–825. [Google Scholar] [CrossRef]
  48. Jayashankar, B.; Rai, K.M.L.; Baskaran, N.; Sathish, H.S. Synthesis and pharmacological evaluation of 1,3,4-oxadiazole bearing bis (heterocycle) derivatives as anti-inflammatory and analgesic agents. Eur. J. Med. Chem. 2009, 44, 3898–3902. [Google Scholar] [CrossRef]
  49. Bhandari, S.V.; Bothara, K.G.; Raut, M.K.; Patil, A.A.; Sarkate, A.P.; Mokale, V.J. Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1,3,4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives. Bioorg. Med. Chem. 2008, 16, 1822–1831. [Google Scholar] [CrossRef]
  50. Singh, A.K.; Lohani, M.; Parthsarthy, R. Synthesis, Characterization and Anti-Inflammatory Activity of Some 1,3,4-Oxadiazole Derivatives. Iran. J. Pharm. Res. 2013, 12, 319–323. [Google Scholar]
  51. Chawla, G.; Naaz, B.; Siddiqui, A.A. Exploring 1,3,4-Oxadiazole Scaffold for Anti-inflammatory and Analgesic Activities: A Review of Literature from 2005–2016. Mini-Rev. Med. Chem. 2018, 18, 216–233. [Google Scholar] [CrossRef]
  52. Somani, R.R.; Shirodkar, P.Y. Oxadiazole: A biologically important heterocycle. Chem. Inform. 2009, 1, 130–140. [Google Scholar]
  53. Verma, G.; Khan, M.F.; Akhtar, W.; Alam, M.M.; Akhter, M.; Shaquiquzzaman, M. A Review Exploring Therapeutic Worth of 1,3,4-Oxadiazole Tailored Compounds. Mini-Rev. Med. Chem. 2019, 19, 477–509. [Google Scholar] [CrossRef]
  54. Maryan, L.; Marta, M.; Myroslava, K.; Iryna, D.; Stefan, H.; Taras, C.; Ihor, C.; Vasyl, M. Approaches for synthesis and chemical modification of non-condensed heterocyclic systems based on 1,3,4-oxadiazole ring and their biological activity: A review. J. Appl. Pharm. Sci. 2020, 10, 151–165. [Google Scholar] [CrossRef]
  55. Sun, J.; Makawana, J.A.; Zhu, H.L. 1,3,4-oxadiazole derivatives as potential biological agents. Mini-Rev. Med. Chem. 2013, 13, 1725–1743. [Google Scholar] [CrossRef]
  56. Bhardwaj, N.; Saraf, S.K.; Sharma, P.; Kumar, P. Syntheses, Evaluation and Characterization of Some 1,3,4-Oxadiazoles as Antimicrobial Agents. E-J. Chem. 2009, 6, 1133–1138. [Google Scholar] [CrossRef]
  57. Patel, K.D.; Prajapati, S.M.; Panchal, S.N.; Patel, H.D. Review of Synthesis of 1,3,4-Oxadiazole Derivatives. Synth. Commun. 2014, 44, 1859–1875. [Google Scholar] [CrossRef]
  58. Croxtall, J.D.; Keam, S.J. Raltegravir: A review of its use in the management of HIV infection in treatment-experienced patients. Drugs 2009, 69, 1059–1075. [Google Scholar] [CrossRef]
  59. Seo, I. Antibacterial Activity of Furamizole on Mycoplasma gallisepticum. Korean J. Vet. Res. 1973, 13, 35–38. [Google Scholar]
  60. Singh, R.; Chouhan, A. Various approaches for synthesis of 1,3,4-Oxadiazole derivatives and their pharmacological activity. World J. Pharm. Sci. 2014, 3, 1474–1505. [Google Scholar]
  61. Fizazi, K.; Higano, C.S.; Nelson, J.B.; Gleave, M.; Miller, K.; Morris, T.; Nathan, F.E.; McIntosh, S.; Pemberton, K.; Moul, J.W. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2013, 31, 1740–1747. [Google Scholar] [CrossRef]
  62. Kumar, S.; Bawa, S.; Gupta, H. Biological activities of quinoline derivatives. Mini-Rev. Med. Chem. 2009, 9, 1648–1654. [Google Scholar] [CrossRef]
  63. Knittel, J.J. Textbook of Organic Medicinal and Pharmaceutical Chemistry. Am. J. Pharm. Educ. 1999, 63, 257. [Google Scholar]
  64. Fournet, A.; Barrios, A.A.; Munoz, V.; Hocquemiller, R.; Cave, A.; Bruneton, J. 2-substituted quinoline alkaloids as potential antileishmanial drugs. Antimicrob. Agents Chemother. 1993, 37, 859–863. [Google Scholar] [CrossRef] [Green Version]
  65. Nicolaou, K.C.; Gross, J.L.; Kerr, M.A. Synthesis of novel heterocycles related to the dynemicin a ring skeleton. J. Heterocycl. Chem. 1996, 33, 735–746. [Google Scholar] [CrossRef]
  66. Bringmann, G.; Reichert, Y.; Kane, V.V. The total synthesis of streptonigrin and related antitumor antibiotic natural products. Tetrahedron 2004, 60, 3539–3574. [Google Scholar] [CrossRef]
  67. Caprio, V.; Guyen, B.; Opoku-Boahen, Y.; Mann, J.; Gowan, S.M.; Kelland, L.M.; Read, M.A.; Neidle, S. A novel inhibitor of human telomerase derived from 10H-indolo [3,2-b]quinoline. Bioorg. Med. Chem. Lett. 2000, 10, 2063–2066. [Google Scholar] [CrossRef]
  68. Mikata, Y.; Yokoyama, M.; Ogura, S.; Okura, I.; Kawasaki, M.; Maeda, M.; Yano, S. Effect of side chain location in (2-aminoethyl)aminomethyl-2-phenylquinolines as antitumor agents. Bioorg. Med. Chem. Lett. 1998, 8, 1243–1248. [Google Scholar] [CrossRef]
  69. Sharples, D.; Spengler, G.; Molnar, J.; Antal, Z.; Molnar, A.; Kiss, J.T.; Szabo, J.A.; Hilgeroth, A.; Gallo, S.; Mahamoud, A.; et al. The interaction between resistance modifiers such as pyrido[3,2-g]quinoline, aza-oxafluorene and pregnane derivatives with DNA, plasmid DNA and tRNA. Eur. J. Med. Chem. 2005, 40, 195–202. [Google Scholar] [CrossRef]
  70. Wolin, R.; Wang, D.; Kelly, J.; Afonso, A.; James, L.; Kirschmeier, P.; McPhail, A.T. Synthesis and evaluation of pyrazolo [3,4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic Ras. Bioorg. Med. Chem. Lett. 1996, 6, 195–200. [Google Scholar] [CrossRef]
  71. Ding, C.Z.; Hunt, J.T.; Ricca, C.; Manne, V. 3-Imidazolylmethylaminophenylsulfonyltetrahydroquinolines, a novel series of farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 273–275. [Google Scholar] [CrossRef]
  72. Wang, Y.D.; Miller, K.; Boschelli, D.H.; Ye, F.; Wu, B.; Floyd, M.B.; Powell, D.W.; Wissner, A.; Weber, J.M.; Boschelli, F. Inhibitors of src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg. Med. Chem. Lett. 2000, 10, 2477–2480. [Google Scholar] [CrossRef] [PubMed]
  73. Senthilkumar, P.; Dinakaran, M.; Yogeeswari, P.; Sriram, D.; China, A.; Nagaraja, V. Synthesis and antimycobacterial activities of novel 6-nitroquinolone-3-carboxylic acids. Eur. J. Med. Chem. 2009, 44, 345–358. [Google Scholar] [CrossRef] [PubMed]
  74. Dinakaran, M.; Senthilkumar, P.; Yogeeswari, P.; China, A.; Nagaraja, V.; Sriram, D. Novel ofloxacin derivatives: Synthesis, antimycobacterial and toxicological evaluation. Bioorg. Med. Chem. Lett. 2008, 18, 1229–1236. [Google Scholar] [CrossRef] [PubMed]
  75. Nayyar, A.; Monga, V.; Malde, A.; Coutinho, E.; Jain, R. Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines. Bioorg. Med. Chem. 2007, 15, 626–640. [Google Scholar] [CrossRef]
  76. Reddy, G.V.; Kanth, S.R.; Maitraie, D.; Narsaiah, B.; Rao, P.S.; Kishore, K.H.; Murthy, U.S.N.; Ravi, B.; Kumar, B.A.; Parthasarathy, T. Design, synthesis, structure-activity relationship and antibacterial activity series of novel imidazo fused quinolone carboxamides. Eur. J. Med. Chem. 2009, 44, 1570–1578. [Google Scholar] [CrossRef]
  77. Guo, L.J.; Wei, C.X.; Jia, J.H.; Zhao, L.M.; Quan, Z.S. Design and synthesis of 5-alkoxy-[1,2,4]triazolo[4,3-a]quinoline derivatives with anticonvulsant activity. Eur. J. Med. Chem. 2009, 44, 954–958. [Google Scholar] [CrossRef]
  78. Clemence, F.; Le Martret, O.; Delevallee, F.; Benzoni, J.; Jouanen, A.; Jouquey, S.; Mouren, M.; Deraedt, R. 4-Hydroxy-3-quinolinecarboxamides with antiarthritic and analgesic activities. J. Med. Chem. 1988, 31, 1453–1462. [Google Scholar] [CrossRef]
  79. Kohno, Y.; Awano, K.; Miyashita, M.; Fujimori, S.; Kuriyama, K.; Sakoe, Y.; Kudoh, S.; Saito, K.; Kojima, E. Synthesis and antirheumatic activity of novel tetrahydroquinoline-8-carboxylic acid derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 1515–1518. [Google Scholar] [CrossRef]
  80. Sircar, I.; Haleen, S.J.; Burke, S.E.; Barth, H. Synthesis and biological activity of 4-(diphenylmethyl)-alpha-[(4-quinolinyloxy)methyl]-1-piperazineethanol and related compounds. J. Med. Chem. 1992, 35, 4442–4449. [Google Scholar] [CrossRef]
  81. Ferlin, M.G.; Chiarelotto, G.; Antonucci, F.; Caparrotta, L.; Froldi, G. Mannich bases of 3H-pyrrolo[3,2-f]quinoline having vasorelaxing activity. Eur. J. Med. Chem. 2002, 37, 427–434. [Google Scholar] [CrossRef]
  82. Hamdani, S.S.; Khan, B.A.; Hameed, S.; Batool, F.; Saleem, H.N.; Mughal, E.U.; Saeed, M. Synthesis and evaluation of novel S-benzyl- and S-alkylphthalimide-oxadiazole-benzenesulfonamide hybrids as inhibitors of dengue virus protease. Bioorg. Chem. 2020, 96, 103567. [Google Scholar] [CrossRef] [PubMed]
  83. Khan, B.A.; Hamdani, S.S.; Ahmed, M.N.; Hameed, S.; Ashfaq, M.; Shawky, A.M.; Ibrahim, M.A.A.; Sidhom, P.A. Synthesis, X-ray diffraction analysis, quantum chemical studies and alpha-amylase inhibition of probenecid derived S-alkylphthalimide-oxadiazole-benzenesulfonamide hybrids. J. Enzym. Inhib. Med. Chem. 2022, 37, 1464–1478. [Google Scholar] [CrossRef]
  84. Khan, B.A.; Zafar, S.; Mughal, E.U.; Ahmed, M.N.; Hamdani, S.S.; Akhtar, T.; Haq, I.U.; Sadiq, A.; Khan, K.M. Design and Synthesis of Novel 1,3,4-oxadiazole Derivatives Bearing Azo Moiety as Biologically Significant Scaffolds. Lett. Drug Des. Discov. 2018, 15, 1346–1355. [Google Scholar] [CrossRef]
  85. Mesiti, F.; Maruca, A.; Silva, V.; Rocca, R.; Fernandes, C.; Remiao, F.; Uriarte, E.; Alcaro, S.; Gaspar, A.; Borges, F. 4-Oxoquinolines and monoamine oxidase: When tautomerism matters. Eur. J. Med. Chem. 2021, 213, 113183. [Google Scholar] [CrossRef]
  86. Zaib, S.; Munir, R.; Younas, M.T.; Kausar, N.; Ibrar, A.; Aqsa, S.; Shahid, N.; Asif, T.T.; Alsaab, H.O.; Khan, I. Hybrid Quinoline-Thiosemicarbazone Therapeutics as a New Treatment Opportunity for Alzheimer’s DiseaseSynthesis, In Vitro Cholinesterase Inhibitory Potential and Computational Modeling Analysis. Molecules 2021, 26, 6573. [Google Scholar] [CrossRef]
  87. Son, S.Y.; Ma, J.; Kondou, Y.; Yoshimura, M.; Yamashita, E.; Tsukihara, T. Structure of human monoamine oxidase A at 2.2-A resolution: The control of opening the entry for substrates/inhibitors. Proc. Natl. Acad. Sci. USA 2008, 105, 5739–5744. [Google Scholar] [CrossRef] [Green Version]
  88. Binda, C.; Wang, J.; Pisani, L.; Caccia, C.; Carotti, A.; Salvati, P.; Edmondson, D.E.; Mattevi, A. Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs. J. Med. Chem. 2007, 50, 5848–5852. [Google Scholar] [CrossRef]
  89. Cheung, J.; Rudolph, M.J.; Burshteyn, F.; Cassidy, M.S.; Gary, E.N.; Love, J.; Franklin, M.C.; Height, J.J. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem. 2012, 55, 10282–10286. [Google Scholar] [CrossRef]
  90. Marti-Renom, M.A.; Stuart, A.C.; Fiser, A.; Sanchez, R.; Melo, F.; Sali, A. Comparative protein structure modeling of genes and genomes. Annu. Rev. Biophys. Biomol. Struct. 2000, 29, 291–325. [Google Scholar] [CrossRef] [Green Version]
  91. Gordon, J.C.; Myers, J.B.; Folta, T.; Shoja, V.; Heath, L.S.; Onufriev, A. H++: A server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005, 33, W368–W371. [Google Scholar] [CrossRef]
  92. Halgren, T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720–729. [Google Scholar] [CrossRef]
  93. OpenEye Scientific Software, SZYBKI 1.9.0.3; OpenEye Scientific Software: Santa Fe, NM, USA, 2016.
  94. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity—A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219–3228. [Google Scholar] [CrossRef]
  95. Forli, S.; Huey, R.; Pique, M.E.; Sanner, M.F.; Goodsell, D.S.; Olson, A.J. Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nat. Protoc. 2016, 11, 905–919. [Google Scholar] [CrossRef] [Green Version]
  96. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30, 2785–2791. [Google Scholar] [CrossRef] [Green Version]
  97. Dassault Systèmes BIOVIA, B.D.S.V. Version 2019; Dassault Systèmes BIOVIA: San Diego, CA, USA, 2019.
  98. Xiong, G.; Wu, Z.; Yi, J.; Fu, L.; Yang, Z.; Hsieh, C.; Yin, M.; Zeng, X.; Wu, C.; Lu, A.; et al. ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021, 49, W5–W14. [Google Scholar] [CrossRef]
  99. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G.A.; et al. Gaussian 09, Revision E01; Gaussian09, Gaussian Inc.: Wallingford, CT, USA, 2009. [Google Scholar]
Pharmaceuticals 16 00011 g001 550
Figure 1. 1,3,4-Oxadiazole as a pharmacophore in commercial and preclinical stage drugs.
Figure 1. 1,3,4-Oxadiazole as a pharmacophore in commercial and preclinical stage drugs.
Pharmaceuticals 16 00011 g001
Pharmaceuticals 16 00011 sch001 550
Scheme 1. Synthesis of S-alkyl phthalimide- and S-benzyl- oxadiazole-quinoline hybrids (5a–f and 6a–d).
Scheme 1. Synthesis of S-alkyl phthalimide- and S-benzyl- oxadiazole-quinoline hybrids (5a–f and 6a–d).
Pharmaceuticals 16 00011 sch001
Pharmaceuticals 16 00011 g002 550
Figure 2. Potent compounds on MAO-A, MAO-B, and AChE enzymes.
Figure 2. Potent compounds on MAO-A, MAO-B, and AChE enzymes.
Pharmaceuticals 16 00011 g002
Pharmaceuticals 16 00011 g003 550
Figure 3. The double reciprocal plot of (a) MAO-A, (b) MAO-B, and (c) AChE activity in the presence and absence of different concentrations of the most promising compounds (5a, 5f, and 5c).
Figure 3. The double reciprocal plot of (a) MAO-A, (b) MAO-B, and (c) AChE activity in the presence and absence of different concentrations of the most promising compounds (5a, 5f, and 5c).
Pharmaceuticals 16 00011 g003
Pharmaceuticals 16 00011 g004 550
Figure 4. (i) 3D molecular interaction of the native structure (in cyan) and the anticipated docking pose (in gray) and (ii) 2D molecular interaction of the anticipated docking pose of (a) harmine with MAO-A, (b) safinamide with MAO-B, and (c) donepezil with AChE.
Figure 4. (i) 3D molecular interaction of the native structure (in cyan) and the anticipated docking pose (in gray) and (ii) 2D molecular interaction of the anticipated docking pose of (a) harmine with MAO-A, (b) safinamide with MAO-B, and (c) donepezil with AChE.
Pharmaceuticals 16 00011 g004
Pharmaceuticals 16 00011 g005 550
Figure 5. Predicted docking scores (in kcal/mol) and docking poses of (a) 5a with MAO-A, (b) 5f with MAO-B, and (c) 5c with AChE.
Figure 5. Predicted docking scores (in kcal/mol) and docking poses of (a) 5a with MAO-A, (b) 5f with MAO-B, and (c) 5c with AChE.
Pharmaceuticals 16 00011 g005
Pharmaceuticals 16 00011 g006 550
Figure 6. Optimized structures of compounds 5a–f and 6a–d.
Figure 6. Optimized structures of compounds 5a–f and 6a–d.
Pharmaceuticals 16 00011 g006
Pharmaceuticals 16 00011 g007 550
Figure 7. Diagrams of HOMO and LUMO distributions of compounds 5a–f and 6a–d.
Figure 7. Diagrams of HOMO and LUMO distributions of compounds 5a–f and 6a–d.
Pharmaceuticals 16 00011 g007
Table
Table 1. IC50 values of synthesized compounds towards MAO-A, MAO-B, and AChE enzymes.
Table 1. IC50 values of synthesized compounds towards MAO-A, MAO-B, and AChE enzymes.
NoCompoundIC50 (μM)
MAO-AMAO-BAChE
15a0.91 ± 0.151.59 ± 1.661.40 ± 0.45
25b1.81 ± 0.382.61 ± 2.482.55 ± 0.96
35c3.31 ± 0.803.39 ± 0.421.02 ± 0.65
45d3.18 ± 1.233.76 ± 1.042.38 ± 0.92
55e4.14 ± 0.353.84 ± 0.911.29 ± 0.75
65f4.88 ± 1.750.84 ± 0.063.32 ± 0.45
76a1.51 ± 0.523.71 ± 2.883.23 ± 0.95
86b1.02 ± 0.922.71 ± 0.883.54 ± 1.05
96c6.81 ± 2.655.59 ± 3.224.38 ± 1.45
106d4.16 ± 1.712.90 ± 1.854.98 ± 1.85
11Clorgyline b0.0045 ± 0.000361.35 ± 1.13
12Deprenyl b67.25 ± 1.020.0196 ± 0.001
13Donepezil b 0.032 ± 0.003 a
a All data are expressed as the average ± SEM of determinations made in triplicate. b Standard inhibitors.
Table
Table 2. Drug-like and ADMET characteristics of potent synthesized molecules and controls a.
Table 2. Drug-like and ADMET characteristics of potent synthesized molecules and controls a.
Compound Physicochemical Properties ADMET Properties
Absorption and Distribution Metab-Olism (CYP2C19 Inhibitor) Excretion (Clearance) Toxicity
(AMES)
MW nHBA nHBD Log P Lipinski Rule HIA CaCo-2 BBB
5a464.1705.2Accepted0.007−4.550.0580.8893.100.043
5c492.1705.4Accepted0.006−4.5340.0780.8623.220.012
5f534.2706.7Accepted0.006−4.5820.0500.8193.460.011
Clorgyline271.1203.7Accepted−0.001−4.2510.9920.67911.240.017
Deprenyl187.1102.7Accepted−0.005−4.9150.9960.13310.460.035
Donepezil379.2404.2Accepted0.003−4.7930.9750.41310.630.026
a MW: Molecular weight; nHBA: number of hydrogen bond acceptors; nHBD: number of hydrogen bond donors; Log P: log of the octanol-water partition coefficient; HIA: Human Intestinal Absorption; CaCo-2: CaCo-2 permeability; BBB: Blood Brain Barrier.
Table
Table 3. Energies of the optimized compounds (Eopt, in au), the highest occupied molecular orbital (EHOMO, in eV), and the lowest unoccupied molecular orbital (ELUMO, in eV), along with energy gap (Egap, in eV). Computed values of global hardness (ƞ), global softness (σ), polarizability (α), and dipole moment (μ) of the studied compounds.
Table 3. Energies of the optimized compounds (Eopt, in au), the highest occupied molecular orbital (EHOMO, in eV), and the lowest unoccupied molecular orbital (ELUMO, in eV), along with energy gap (Egap, in eV). Computed values of global hardness (ƞ), global softness (σ), polarizability (α), and dipole moment (μ) of the studied compounds.
CompoundEopt
(au)		EHOMO (eV)ELUMO (eV)∆Egap
(eV)		η
(eV)		σ
(eV−1)		μ
(Debye)		α
5a−1842.831−0.221−0.1120.1080.0549.2068.358347.284
5b−1882.144−0.221−0.1090.1120.0568.9177.599351.377
5c−1921.445−0.226−0.1000.1250.0637.9556.751363.499
5d−1960.751−0.226−0.0980.1270.0647.8467.320370.377
5e−2000.055−0.225−0.0960.1290.0657.7216.769385.049
5f−2039.360−0.225−0.0950.1300.0657.6517.268393.625
6a−1899.057−0.227−0.0890.1370.0697.2661.194331.243
6b−1899.057−0.227−0.0880.1380.0697.2372.973329.504
6c−1899.059−0.226−0.0880.1380.0697.2452.446323.636
6d−1562.098−0.223−0.0840.1380.0697.2043.093318.962
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Khan, B.A.; Hamdani, S.S.; Jalil, S.; Ejaz, S.A.; Iqbal, J.; Shawky, A.M.; Alqahtani, A.M.; Gabr, G.A.; Ibrahim, M.A.A.; Sidhom, P.A. Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase. Pharmaceuticals 2023, 16, 11. https://doi.org/10.3390/ph16010011

AMA Style

Khan BA, Hamdani SS, Jalil S, Ejaz SA, Iqbal J, Shawky AM, Alqahtani AM, Gabr GA, Ibrahim MAA, Sidhom PA. Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase. Pharmaceuticals. 2023; 16(1):11. https://doi.org/10.3390/ph16010011

Chicago/Turabian Style

Khan, Bilal Ahmad, Syeda Shamila Hamdani, Saquib Jalil, Syeda Abida Ejaz, Jamshed Iqbal, Ahmed M. Shawky, Alaa M. Alqahtani, Gamal A. Gabr, Mahmoud A. A. Ibrahim, and Peter A. Sidhom. 2023. "Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase" Pharmaceuticals 16, no. 1: 11. https://doi.org/10.3390/ph16010011

APA Style

Khan, B. A., Hamdani, S. S., Jalil, S., Ejaz, S. A., Iqbal, J., Shawky, A. M., Alqahtani, A. M., Gabr, G. A., Ibrahim, M. A. A., & Sidhom, P. A. (2023). Synthesis and Evaluation of Novel S-alkyl Phthalimide- and S-benzyl-oxadiazole-quinoline Hybrids as Inhibitors of Monoamine Oxidase and Acetylcholinesterase. Pharmaceuticals, 16(1), 11. https://doi.org/10.3390/ph16010011

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop